Collegium Pharmaceutical, Inc. (COLL) Quick Ratio
- Quick ratio · latest quarter: Value 0.70×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 0.70× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $414.57M ÷ $589.86M ≈ 0.70× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 414.57M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 589.86M USD | Liabilities, Current |
| Cash and equivalents | 129.47M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 285.10M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 113.27M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $414.57M | $589.86M | $129.47M | $0.00 | $285.10M | $113.27M | 0.70× |
| 2026-03-31 | $650.51M | $434.97M | $268.65M | $153.10M | $228.76M | $42.74M | 1.50× |
| 2025-12-31 | $598.01M | $440.03M | $231.25M | $155.43M | $211.33M | $40.91M | 1.36× |
| 2025-09-30 | $519.81M | $452.93M | $150.10M | $135.77M | $233.95M | $38.05M | 1.15× |
| 2025-06-30 | $435.18M | $464.61M | $117.35M | $104.81M | $213.02M | $38.15M | 0.94× |
| 2025-03-31 | $426.48M | $486.71M | $96.19M | $101.58M | $228.71M | $37.22M | 0.88× |
| 2024-12-31 | $391.30M | $509.51M | $70.56M | $92.20M | $228.54M | $35.56M | 0.77× |
| 2024-09-30 | $348.41M | $459.43M | $38.96M | $81.00M | $228.46M | $38.03M | 0.76× |
| 2024-06-30 | $455.49M | $461.72M | $172.89M | $98.74M | $183.85M | $27.86M | 0.99× |
| 2024-03-31 | $492.74M | $446.44M | $228.61M | $89.44M | $174.69M | $31.28M | 1.10× |
| 2023-12-31 | $490.07M | $457.92M | $238.95M | $71.60M | $179.53M | $32.33M | 1.07× |
| 2023-09-30 | $486.42M | $464.61M | $258.53M | $46.03M | $181.85M | $34.13M | 1.05× |
| 2023-06-30 | $492.95M | $435.06M | $283.75M | $41.72M | $167.48M | $26.03M | 1.13× |
| 2023-03-31 | (m) | $412.70M | $269.48M | (m) | $179.13M | $32.90M | (m) |
| 2022-12-31 | (m) | $433.73M | $173.69M | (m) | $183.12M | $46.50M | (m) |
| 2022-09-30 | (m) | $414.50M | $134.13M | (m) | $195.40M | $64.65M | (m) |
| 2022-06-30 | (m) | $415.09M | $122.72M | (m) | $197.50M | $77.77M | (m) |
| 2022-03-31 | (m) | $373.57M | $106.70M | (m) | $166.34M | $80.15M | (m) |
| 2021-12-31 | (m) | $279.57M | $186.43M | (m) | $105.84M | $17.39M | (m) |
| 2021-09-30 | (m) | $268.97M | $193.24M | (m) | $149.00M | $17.36M | (m) |
| 2021-06-30 | (m) | $226.84M | $202.77M | (m) | $90.10M | $19.59M | (m) |
| 2021-03-31 | (m) | $230.17M | $182.79M | (m) | $93.16M | $15.50M | (m) |
| 2020-12-31 | (m) | $239.45M | $174.12M | (m) | $83.32M | $15.61M | (m) |
| 2020-09-30 | (m) | $242.44M | $165.42M | (m) | $76.47M | $17.15M | (m) |
| 2020-06-30 | (m) | $252.11M | $145.68M | (m) | $81.19M | $18.82M | (m) |
| 2020-03-31 | (m) | $244.37M | $116.18M | (m) | $85.43M | $15.96M | (m) |
| 2019-12-31 | (m) | $201.76M | $170.02M | (m) | $72.95M | $9.64M | (m) |
| 2019-09-30 | (m) | $201.48M | $153.84M | (m) | $84.38M | $8.76M | (m) |
| 2019-06-30 | (m) | $196.27M | $148.71M | (m) | $81.28M | $9.95M | (m) |
| 2019-03-31 | (m) | $188.88M | $134.91M | (m) | $85.14M | $8.74M | (m) |
| 2018-12-31 | (m) | $189.13M | $146.63M | (m) | $77.95M | $7.82M | (m) |
| 2018-09-30 | (m) | $280.22M | $139.79M | (m) | $66.53M | $9.23M | (m) |
| 2018-06-30 | (m) | $264.70M | $133.75M | (m) | $68.38M | $8.54M | (m) |
| 2018-03-31 | (m) | $250.23M | $128.25M | (m) | $66.04M | $7.90M | (m) |
| 2017-12-31 | (m) | $31.49M | $118.70M | (m) | $9.97M | $1.81M | (m) |
| 2017-09-30 | (m) | $26.40M | $107.61M | (m) | $5.82M | $1.40M | (m) |
| 2017-06-30 | (m) | $28.56M | $111.21M | (m) | $4.88M | $1.52M | (m) |
| 2017-03-31 | (m) | $24.53M | $129.56M | (m) | $3.35M | $1.50M | (m) |
| 2016-12-31 | (m) | $25.60M | $153.22M | (m) | $2.13M | $1.32M | (m) |
| 2016-09-30 | (m) | $22.21M | $91.03M | (m) | $1.68M | $1.58M | (m) |
| 2016-06-30 | (m) | $18.20M | $110.75M | (m) | $2.95M | $1.21M | (m) |
| 2016-03-31 | (m) | $11.07M | $134.73M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $8.43M | $95.70M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $8.60M | $105.46M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $6.19M | $112.41M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $6.71M | $44.99M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $10.42M | $1.63M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $4.18M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $2.59M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $4.81M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $7.55M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $11.94M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |